AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer
AstraZeneca’s big comeback year just got better.
After disappointing investors with repeated setbacks on their PD-L1/CTLA-4 matchup of Imfinzi and tremelimumab, the pharma giant said Monday that the combo — combined with a choice of chemotherapies — worked in delaying disease progression in frontline cases of Stage 4 non-small cell lung cancer, hitting a key endpoint in the closely-watched POSEIDON study. And on the primary, Imfinzi and chemo together also hit on the progression-free survival yardstick.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.